Browsing category:

Patent Expiration 2018


Clofarabine, CAS# 123318-82-1, is also known as the brand name Clolar. As an injectable medication used to treat relapsed or refractory acute lymphoblastic leukemia, clofarabine is typically administered after at least two prior regimens. Clofarabine is indicated for the pediatric population, ages 1 to 21 years of age. A common treatment regimen is 52 mg/m2[…]

Read More

Canadian Patients got good news on April 10, 2013 when the availability of Mirabegron for OAB (Overactive Bladder) was announced. “Now that Myrbetriq is available through pharmacies, Canadian patients have access to the first new class of medication for the treatment of OAB in over 30 years,” said Michael Tremblay, President, Astellas Pharma Canada, Inc.  Astellas[…]

Read More

At the 28th Annual EAU Congress, held in mid- March 2013 some startling statistic regarding men suffering from Erectile Dysfunction were revealed. Known also as ED, Erectile Dysfunction plagues almost 88 million men worldwide.  Shocking numbers from a large clinical study of a subset of these patients, specifically a little over 6 million men, showed[…]

Read More

What if patients with acute pain could utilize a nasal spray to ease their discomfort? That is exactly what can be done when patients are given Ketorolac Tromethamine CAS# 74103-06-3. Known as the brand name Sprix, this intranasal solution for acute pain is not only novel, it is also proving to be efficacious. Some distinct[…]

Read More

Breaking news in the pharmaceutical world made headlines on June 12, 2013, when the Centers for Disease Control and Prevention revealed a study touting the prophylactic benefit of Tenofovir. Coined pre-exposure prophylaxis or PrEP, this study advocating the use of Tenofovir as an interventional pre-treatment was published in the Lancet in mid- June of 2013.[…]

Read More

Famotidine, CAS number 76824-35-6, is an effective, tolerable and well- studied treatment for patients with both peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Schwarz Pharma holds the patent for this cogent medication, as the brand name Fluxid, with an expiration due on April 9, 2018.  As an H2 receptor, or histamine blocker receptor,[…]

Read More

The latest news regarding divalproex sodium is exciting for patients who suffer from migraine headaches. A new set of guidelines were published in the April 24, 2012 issue of Neurology, and presented at the academy’s annual meeting in New Orleans April 21 to 28, 2013.  The new guidelines are composed of information from 29 studies[…]

Read More

Fenofibrate, CAS number 49562-28-9, is known as the brand name Lipofen, which is marketed by Cipher-Kowa Pharmaceuticals. The patent for Lipofen is due to expire on January 10, 2015. Other recognizable brands of fenofibrate are Tricor, which has a patent expiration of January 9, 2018 and Antara, which has a patent expiration set for August[…]

Read More